An oral (pill) GLP-1 medication from Eli Lilly, sold under the brand name Foundayo, approved for weight management in 2026. Unlike injectable GLP-1s and the older oral semaglutide, it's a small-molecule pill without strict food-and-water timing rules, which makes it attractive to needle-averse patients. Being new, its long-term and real-world data are still accumulating.
Related terms: Foundayo (orforglipron) · Semaglutide · Rybelsus